[go: up one dir, main page]

PL1912626T3 - Postaci użytkowe o polepszonej biodostępności - Google Patents

Postaci użytkowe o polepszonej biodostępności

Info

Publication number
PL1912626T3
PL1912626T3 PL06776679.0T PL06776679T PL1912626T3 PL 1912626 T3 PL1912626 T3 PL 1912626T3 PL 06776679 T PL06776679 T PL 06776679T PL 1912626 T3 PL1912626 T3 PL 1912626T3
Authority
PL
Poland
Prior art keywords
dosage forms
improved bioavailability
bioavailability
improved
dosage
Prior art date
Application number
PL06776679.0T
Other languages
English (en)
Inventor
Gunther Berndl
Matthias Degenhardt
Markus Mägerlein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL1912626T3 publication Critical patent/PL1912626T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06776679.0T 2005-08-08 2006-08-08 Postaci użytkowe o polepszonej biodostępności PL1912626T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59581805P 2005-08-08 2005-08-08

Publications (1)

Publication Number Publication Date
PL1912626T3 true PL1912626T3 (pl) 2016-10-31

Family

ID=37122088

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06776679.0T PL1912626T3 (pl) 2005-08-08 2006-08-08 Postaci użytkowe o polepszonej biodostępności

Country Status (9)

Country Link
US (2) US20090028938A1 (pl)
EP (1) EP1912626B1 (pl)
JP (1) JP2009504590A (pl)
CA (1) CA2618264C (pl)
DK (1) DK1912626T3 (pl)
ES (1) ES2576633T3 (pl)
PL (1) PL1912626T3 (pl)
PT (1) PT1912626T (pl)
WO (1) WO2007017249A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
MX2007009088A (es) 2005-01-27 2007-09-13 Alembic Ltd Formulacion de liberacion extendida de levetiracetam.
JP5243247B2 (ja) * 2005-07-28 2013-07-24 アイエスピー インヴェストメンツ インコーポレイテッド スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品
CA2618255C (en) 2005-08-08 2015-05-26 Abbott Gmbh & Co. Kg Itraconazole compositions with improved bioavailability
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
TWI583405B (zh) * 2008-02-28 2017-05-21 艾伯維有限公司 錠劑及其製備
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
JP2015524395A (ja) 2012-07-17 2015-08-24 ダウ グローバル テクノロジーズ エルエルシー 有機液体希釈剤および粘度の非常に低いセルロースエーテルを含む組成物
US20140024723A1 (en) * 2012-07-17 2014-01-23 Dow Global Technologies Llc Composition comprising an organic liquid diluent and a specific hydroxypropyl methylcellulose
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US9980946B1 (en) * 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
WO2020018959A1 (en) 2018-07-19 2020-01-23 Impel Neuropharma, Inc. Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
AU665988B2 (en) 1992-03-18 1996-01-25 Janssen Pharmaceutica N.V. Itraconazole and saperconazole stereoisomers
PL189122B1 (pl) * 1995-11-23 2005-06-30 Janssen Pharmaceutica Nv Sposób wytwarzania mieszaniny stałej zawierającejjedną lub wiele cyklodekstryn, mieszanina stała ikompozycja farmaceutyczna
CN1165291C (zh) * 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
HUP0004139A3 (en) * 1997-11-03 2002-03-28 Janssen Pharmaceutica Nv Compositions of lipid lowering agents containing water-soluble polimer
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
JP4997683B2 (ja) * 2000-09-25 2012-08-08 日本新薬株式会社 医薬固体分散体の製法
MXPA05005736A (es) * 2002-12-17 2005-08-16 Abbott Gmbh & Co Kg Formulacion que comprende acido fenofibrico, una sal fisiologicamente aceptable o derivado del mismo.
AU2003286372A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2618255C (en) 2005-08-08 2015-05-26 Abbott Gmbh & Co. Kg Itraconazole compositions with improved bioavailability

Also Published As

Publication number Publication date
EP1912626A1 (en) 2008-04-23
US20090028938A1 (en) 2009-01-29
CA2618264A1 (en) 2007-02-15
US20110311595A1 (en) 2011-12-22
PT1912626T (pt) 2016-07-20
WO2007017249A1 (en) 2007-02-15
ES2576633T3 (es) 2016-07-08
DK1912626T3 (en) 2016-08-01
EP1912626B1 (en) 2016-04-13
CA2618264C (en) 2015-11-24
US9060936B2 (en) 2015-06-23
JP2009504590A (ja) 2009-02-05

Similar Documents

Publication Publication Date Title
PT1912626T (pt) Formas farmacêuticas com biodisponibilidade melhorada
IL251539A0 (en) Single pharmaceutical dosage form
GB0501999D0 (en) Pharmaceutical compounds
GB0520657D0 (en) Pharmaceutical compounds
IL184858A0 (en) Alcohol resistant dosage forms
GB0508306D0 (en) Nicotine dosage forms
AP2008004533A0 (en) Pharmaceutical combination
GB0520656D0 (en) Pharmaceutical compounds
ZA200800368B (en) New pharmaceutical compounds
GB0427455D0 (en) Dosage forms
GB0513984D0 (en) Dosage form
ZA200804666B (en) Pharmaceutical combination
GB0512643D0 (en) Pharmaceutical compounds
TWI372053B (en) Combination drug
ZA200705612B (en) Pharmaceutical compounds
GB0512246D0 (en) Novel pharmaceutical
GB0501475D0 (en) Pharmaceutical compounds
GB0522989D0 (en) Dosage form
GB0507474D0 (en) Pharmaceutical compounds
GB0501748D0 (en) Pharmaceutical compounds
GB0516790D0 (en) Pharmaceutical compounds
GB0516167D0 (en) Pharmaceutical compounds
GB0512681D0 (en) Pharmaceutical compounds
GB0501729D0 (en) Pharmaceutical compounds
GB0511884D0 (en) Pharmaceutical compounds